Telitacicept reduces proteinuria in adults with IgA nephropathy in Phase 3 trial
New Drug Slashes Kidney Damage Risk in IgA Nephropathy Patients
This is an interim analysis of a Phase 3, multicenter, randomized, placebo-controlled trial in 318 adults with IgA nephropathy and persisten…
A targeted therapy reduced protein in urine by 55 percent more than placebo in people with IgA nephropathy, offering new hope for slowing ki…
Network meta-analysis compares biologics and targeted drugs for systemic lupus erythematosus efficacy and safety
New Lupus Treatments Show Stronger Results With Fewer Side Effects
This systematic review and network meta-analysis of 17,121 patients with systemic lupus erythematosus compared biologics and targeted small …
Certain new lupus drugs help more people feel better with fewer flare-ups, especially those struggling with rashes or joint pain that older …
Telitacicept plus standard therapy in SLE patients with antiphospholipid antibodies
New Lupus Drug May Help Patients With Specific Antibodies
This prospective observational cohort study evaluated telitacicept added to standard therapy in 20 SLE patients with antiphospholipid antibo…
A new treatment shows promise for a tough lupus group by targeting specific immune cells.